Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5532860 | 0.94 | ALOX5AP (0.69) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL5529433 | 0.93 | ALOX5AP (0.79) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL5535141 | 0.92 | ALOX5AP (0.69) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL5537799 | 0.91 | ALOX5AP (0.74) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL3462108 | 0.90 | ALOX5AP (0.69) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL5527825 | 0.90 | ALOX5AP (0.76) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL3463819 | 0.89 | ALOX5AP (0.74) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL5532174 | 0.89 | ALOX5AP (0.86) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL5537696 | 0.89 | ALOX5AP (0.69) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL5522556 | 0.88 | ALOX5AP (0.74) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | claimed |
| EP-2144875-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | Amira Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008137609-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219206-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885CYP3A4 912/4885CYP2C9 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.